OAKDALE, Minn.--(BUSINESS WIRE)--BlueAllele® Corporation, a biotechnology company focused on advancing transformational gene editing technologies, filed a patent infringement lawsuit against Intellia Therapeutics in the United States District Court for the District of Delaware. The complaint alleges infringement of BlueAllele’s bi-directional insertion template patents, which cover the company’s transformational platform used in the development and treatment of genetic diseases. The novel desig...
Read the full news release here